Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Prelude Therapeutics Incorporated is currently navigating 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are located in 2 distinct art units, which suggests that the company's pharmaceutical developments span different chemical or biological classifications. The involvement of 2 distinct examiners means that the prosecution is not centralized under a single person. This distribution across 2 distinct art units highlights the varied nature of the company's current patent applications.
O DELL, DAVID K is the busiest examiner for this portfolio, currently handling 1 pending office action. The 2 pending office actions are divided between the 2 distinct examiners, resulting in a balanced distribution of the current workload. Since the pending office actions are being reviewed in 2 distinct art units, practitioners should be prepared for different technical requirements and examination standards. The 1 pending office action assigned to O DELL, DAVID K requires a strategy tailored to that examiner's specific approach in the Biotechnology & Pharmaceuticals sector. Coordinating between the 2 distinct examiners is necessary to maintain a unified prosecution strategy. This structure ensures that each of the 2 pending office actions receives specialized attention within its respective art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18928257 | CDK Inhibitors And Their Use As Pharmaceuticals | O DELL, DAVID K | — |
| 18508666 | BRM Targeting Compounds and Associated Methods of Use | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18928257 | CDK Inhibitors And Their Use As Pharmaceuticals | O DELL, DAVID K | 1621 | §112DP | Non-Final OA | — | Pending | Oct 28, 2024 |
| 18508666 | BRM Targeting Compounds and Associated Methods of Use | LEE, WILLIAM Y | 1623 | §112DP | Non-Final OA | — | Pending | Nov 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPrelude Therapeutics Incorporated has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
David K O Dell has the most, with 1 of Prelude Therapeutics Incorporated's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
